Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
4.980
-0.250 (-4.78%)
Jul 24, 2026, 2:49 PM EDT - Market open
Seres Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 29.83 | 45.77 | 30.79 | 127.97 | 163.03 | 180 |
Short-Term Investments | - | - | - | - | 18.31 | 110.7 |
Cash & Short-Term Investments | 29.83 | 45.77 | 30.79 | 127.97 | 181.34 | 290.71 |
Cash Growth | -49.30% | 48.63% | -75.94% | -29.43% | -37.62% | 14.62% |
Accounts Receivable | 0.23 | 0.16 | - | - | - | - |
Other Receivables | - | 0.36 | 2.07 | - | - | - |
Total Trade Receivables | 0.23 | 0.52 | 2.07 | - | - | - |
Other Current Assets | 1.77 | 3.09 | 5.81 | 47.45 | 13.42 | 12.92 |
Total Current Assets | 31.84 | 49.38 | 38.67 | 175.41 | 194.76 | 303.63 |
Net Property, Plant & Equipment | 77.08 | 80.12 | 92.44 | 108.03 | 133.97 | 36.15 |
Long-Term Investments | - | - | - | - | - | 0.5 |
Other Long-Term Assets | 8.7 | 8.7 | 8.7 | 75.16 | 20.05 | 14.59 |
Total Assets | 117.62 | 138.19 | 139.81 | 358.6 | 348.78 | 354.86 |
Accounts Payable | 2.34 | 1.68 | 4.08 | 3.64 | 17.44 | 13.74 |
Accrued Expenses | 6.14 | 7.25 | 28.47 | 22.51 | 59.84 | 45.09 |
Current Portion of Long-Term Debt | - | - | - | - | 0.46 | - |
Current Portion of Leases | 10.87 | 10.39 | 8.67 | 5.59 | 3.6 | 6.61 |
Unearned Revenue | - | - | - | - | 4.26 | 16.82 |
Other Current Liabilities | - | - | - | 66.92 | - | - |
Total Current Liabilities | 19.34 | 19.32 | 41.22 | 98.66 | 85.6 | 82.26 |
Long-Term Debt | - | - | - | 101.54 | 50.59 | 24.64 |
Long-Term Leases | 69.63 | 72.58 | 82.97 | 91.65 | 107.94 | 17.96 |
Other Long-Term Liabilities | 2.14 | 2.08 | 1.84 | 111.6 | 93.87 | 98.49 |
Total Long-Term Liabilities | 71.78 | 74.65 | 84.8 | 304.8 | 252.41 | 141.09 |
Total Liabilities | 91.12 | 93.98 | 126.03 | 403.46 | 338 | 223.35 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.14 | 0.13 | 0.09 |
Additional Paid-in Capital | 1,019 | 1,017 | 991.87 | 933.24 | 875.18 | 745.83 |
Accumulated Other Comprehensive Income | - | - | - | - | -0.01 | -0.06 |
Retained Earnings | -992.32 | -972.4 | -978.1 | -978.24 | -864.51 | -614.35 |
Shareholders' Equity | 26.5 | 44.22 | 13.78 | -44.86 | 10.78 | 131.51 |
Total Liabilities & Equity | 117.62 | 138.19 | 139.81 | 358.6 | 348.78 | 354.86 |
Total Debt | 80.5 | 82.97 | 91.64 | 198.78 | 162.59 | 49.21 |
Net Cash (Debt) | -50.67 | -37.2 | -60.85 | -70.82 | 18.75 | 241.5 |
Net Cash Growth | - | - | - | - | -92.23% | 13.46% |
Net Cash Per Share | -5.58 | -4.19 | -7.83 | -11.06 | 3.47 | 52.67 |
Book Value | 26.5 | 44.22 | 13.78 | -44.86 | 10.78 | 131.51 |
Book Value Per Share | 2.92 | 4.99 | 1.77 | -7.01 | 2.00 | 28.68 |
Tangible Book Value | 26.5 | 44.22 | 13.78 | -44.86 | 10.78 | 131.51 |
Tangible Book Value Per Share | 2.92 | 4.99 | 1.77 | -7.01 | 2.00 | 28.68 |